Kite Pharma EU
Division of Gilead Sciences Inc.
Latest From Kite Pharma EU
Regeneron and Shire should find out this week whether the European Medicines Agency will agree to fast-track its review of their products.
Products submitted for approval in the EU in recent weeks include Amgen/UCB’s potential new treatment for osteoporosis, romosozumab, an iv formulation of GSK’s flu treatment, zanamivir, and avacopan, a new immunosuppressant from ChemoCentryx that is getting support through the EMA’s PRIME scheme.
Lilly’s migraine prevention therapy, galcanezumab, is among the nine new products that companies have submitted to the European Medicines Agency for evaluation in recent weeks.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- T-Cell Factory BV
- Western Europe
- Parent & Subsidiaries
- Gilead Sciences Inc.
- Senior Management
- Contact Info
Kite Pharma EU
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.